Humacyte, Inc. — Director's Dealing 2024

Aug 30, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2024-08-27

Reporting Person: Sander Dale A. (CFO and Chief Corp. Deve. Off.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-27	Common Stock	M	39389	$2.56	Acquired	41389	Direct
2024-08-27	Common Stock	S	39389	$6.68	Disposed	2000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-27	Stock Options (right to buy)	$2.56	M	39389	Disposed	2025-09-01	Common Stock (39389)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20600	Indirect

Footnotes

F1: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.